Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003
- Conditions
- First Posted Date
- 2010-04-06
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 54
- Registration Number
- NCT01099267
- Locations
- 🇺🇸
Stanford University Cancer Center, Stanford, California, United States
🇺🇸Cancer & Blood Disease Center, Lecanto, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Connect® MM- The Multiple Myeloma Disease Registry
- Conditions
- Interventions
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Celgene
- Target Recruit Count
- 3311
- Registration Number
- NCT01081028
- Locations
- 🇺🇸
Mid Ohio Oncology/Hematology, Inc, Columbus, Ohio, United States
🇺🇸The Methodist Hospital Research Institute-AOCT, Houston, Texas, United States
🇺🇸Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
- Conditions
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1494
- Registration Number
- NCT01081015
- Locations
- 🇺🇸
Cancer Care Partners, LLC, Mishawaka, Indiana, United States
🇺🇸Illinois Cancer Care, Peoria, Illinois, United States
🇺🇸McFarland Clinic, Ames, Iowa, United States
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 488
- Registration Number
- NCT01074047
- Locations
- 🇧🇪
Grand Hôpital de Charleroi, Charleroi, Hainaut, Belgium
🇦🇹Wilhelminenspital, I Medizinische Abt., Wien, Vienna, Austria
🇵🇱Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku, Wroclaw, Dolnoslaskie, Poland
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 51
- Registration Number
- NCT01032291
- Locations
- 🇧🇪
ULB Erasme Service de Gastroenterologie, Brussels, Belgium
🇮🇹Azienda Osperdaliero Universitaria Riuniti Umberto I-GM Lancisi-G. Salesi di Ancona Clinica di Oncologia Medica, Ancona, Italy
🇧🇪Grand hôpital de Charleroi, Oncologie, Charleroi, Belgium
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 239
- Registration Number
- NCT01029262
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇨🇦Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
🇺🇸Southern Illinois Hematology Oncology, Centralia, Illinois, United States
A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).
- Conditions
- Interventions
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 9
- Registration Number
- NCT01021423
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1059
- Registration Number
- NCT00988208
- Locations
- 🇺🇸
Cookeville Regional Medical Center, Cookeville, Tennessee, United States
🇺🇸Veterans Education and Research Association of Northern New England, Inc., White River Junction, Vermont, United States
🇦🇹Medizinische Universitat Wien, Vienna, Austria
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT00975806
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Cleveland Clinic Main Campus, Cleveland, Ohio, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Celgene
- Target Recruit Count
- 104
- Registration Number
- NCT00963105
- Locations
- 🇺🇸
Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States
🇺🇸Cancer Center of Central Connecticut, Southington, Connecticut, United States
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada